Sdi Limited · ASX:SDI
Sdi — Market Eye Conference (December 2020)
12 slides from Sdi's conference presentation, Dec 1, 2020
Slide 1: Market Eye Conference
Market Eye Conference Addressing global health challenges through innovation 1 December 2020 Samantha Cheetham CEO
Slide 2: Your Smile. Our Vision.
YOUR SMILE. OUR VISION. Long successful operating SDI conducts research and SDI sells to 100+ countries history – founded in 1972 development of specialist on all continents and with and listed on ASX in 1985 dentist materials undertaking sales teams and distribution and Australia’s largest the deve
Slide 3: Global Health Challenge in Dentistry
GLOBAL HEALTH CHALLENGE IN DENTISTRY o Dental caries is a major public health problem globally, the most widespread noncommunicable disease o Dental caries consumed 5-10% of healthcare budgets in industrialised countries. A main reason for hospitalisation of children in some high-income countries o
Slide 4: Addressing the Problem with Innovation
ADDRESSING THE PROBLEM WITH INNOVATION o Riva Star, a silver diamine fluoride or SDF, assists with stopping decay o Riva restoratives (“fillings”) and cements release fluoride and calcium to the tooth, making teeth stronger and o All research and development is focused on developing stronger product
Slide 5: Product Categories
PRODUCT CATEGORIES
Slide 6: Product Mix
PRODUCT MIX Product Sales $m o Significant product shift as a result of $90 strategic shift and redirected research $80 and development $70 o Contemporary products (Aesthetics and $60 $50 12.4 30.9 Whitening) have moved from 43% of $40 11.8 sales to 73% of sales with ~10% CAGR $30 5.6 18.1 in revenu
Slide 7: Category Overview
CATEGORY OVERVIEW MOMENTUM IMPACTED BY COVID-19 WITH PRODUCT MIX CONTINUING TO DRIVE GROSS MARGIN o Government restrictions impacted demand in all product Gross Margins % groups, with dentists limited to emergency procedures 66% 64.8% o Record Sales momentum in 1H20 impacted by global 64% pandemic i
Slide 8: Geographies
GEOGRAPHIES Sales by geography (A$m) 27.6 23.7 19.2 Europe North America $23.7m (14.0%) 14.7 14.2 14.6 $14.6m (23.9%) Middle East/Africa 8.7 9.4 $6.9m (20.7%) 8.0 APAC 6.9 $14.2m (3.7%) South America $8.0m (14.3%) APAC Middle South North Europe East / America America Africa FY19 FY20 8
Slide 9: FY20 Summary
FY20 SUMMARY GROWTH MOMENTUM IMPACTED BY COVID-19 IN 2H20 Sales ($m) EBITDA ($M) 79.6 14.2 74.1 74.5 12.5 12.1 7.8 42.5 67.4 39.7 40.9 7.6 8.6 27.4 9.8 2.7 40.0 6.4 7.1 34.4 33.6 37.1 4.9 3.6 FY17 FY18 FY19 FY20 FY17 FY18 FY19 FY20 H1 ($m) H2 ($m) H1 ($m) H2 ($m) o Sales down 15.4% to $67.4m with 2H
Slide 10: Trading Update
TRADING UPDATE STRONG START TO THE FINANCIAL YEAR o Strong first quarter in most regions (local currency) • Australia Domestic up 28% • North America up 15% • Brazil up 37% • Europe (ex-UK) up 25% • UK down 80% • Australian Direct Exports down 22% • Total sales down 1% o Operating Expenses down 20%
Slide 11: Strategy & Outlook
STRATEGY & OUTLOOK CLEAR STRATEGY AND POSITIVE OUTLOOK STRATEGY o 45% SKUs reduction expected to drive further efficiencies o On-going investment in R&D with the release 1-2 products per year o Pola Light USA and Australian launches performing very well o Amalgam replacement product on schedule for
Slide 12: Disclaimer
Disclaimer This Presentation contains summary information about SDI Limited (SDI) and its subsidiaries and their activities. The information in this Presentation does not purport to be complete. It should be read in conjunction with SDI’s other periodic and continuous disclosure announcements lodged